Nanomolar TLR4 Antagonist CIAC101 Derived from (+)-Naltrexone Blocks Microglial Activation and Methamphetamine Addiction

Substance use disorders, including methamphetamine (METH) addiction, are increasingly linked to neuroimmune activation mediated by Toll-like receptor 4 (TLR4). While (+)-naltrexone is known to antagonize TLR4 without acting on opioid receptors, its low potency has historically limited its clinical utility. This study aimed to identify a more potent, central nervous system (CNS)-penetrant (+)-naltrexone derivative to effectively treat METH addiction through neuroimmune modulation.

The researchers utilized a dual-site structural optimization strategy, modifying the C3 and N17 positions of the (+)-naltrexone scaffold. Through systematic structure-activity relationship (SAR) analysis, they synthesized a series of derivatives and evaluated their ability to inhibit LPS-induced nitric oxide (NO) production in BV-2 microglial cells. The lead candidate, CIAC101, was further characterized for its ability to suppress NF-κB signaling, reduce pro-inflammatory cytokines, and inhibit addiction-like behaviors (locomotor sensitization and conditioned place preference) in METH-treated mice. Pharmacokinetics and safety profiles were also assessed.

CIAC101 emerged as a nanomolar TLR4 antagonist, demonstrating approximately 6200-fold higher potency than (+)-naltrexone. In vitro, it robustly suppressed NF-κB activation and decreased mRNA expression of inflammatory markers like iNOS, IL-1β, TNF-α, and IL-6. In vivo, low-dose CIAC101 (0.2 mg/kg) significantly attenuated METH-induced behavioral sensitization and conditioned place preference. Importantly, mechanistic studies showed that CIAC101 reduced microglial activation and cytokine levels specifically in addiction-relevant brain circuits, such as the medial prefrontal cortex (mPFC) and ventral tegmental area (VTA). The compound exhibited favorable blood-brain barrier penetration and appeared well-tolerated at doses 100-fold higher than the therapeutic dose.